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length of stay in the hospital is about 3.5 days. CONCLUSIONS: After the logistic and
linear regressions, the results showed a small correlation with cellulitis. The likelihood 
of having a bacterial infection or having infections with microorganisms increases with 
cellulitis. The likelihood of having a venous catheterization, having the skin drained,
or having the tendon sheath of the hand explored increases with cellulitis.
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THE ECONOMIC IMPACT OF TRANSITIONING VALACYCLOVIR TO OVER
THE COUNTER STATUS FOR THE TREATMENT OF GENITAL HERPES
Chang JY, Nichol MB
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OBJECTIVES: Genital herpes affects more than 45 million individuals in the United 
States with an estimated 400,000 physician ofﬁ ce visits each year for primary infec-
tions. With no cure for the herpes infection, it can be transmitted from the infected 
individuals to the unsuspecting population throughout the lifetime of the infected.
With the approaching patent expiration for the prescription drug valacyclovir 
(Valtrex) in 2009, this study examines the implications of transitioning valacyclovir 
to an over the counter (OTC) status. METHODS: A decision analysis model was used
to examine the current prescription based requirement for valacyclovir compared to 
the OTC status for the product. The analysis was constructed from a societal perspec-
tive using a budget impact model. A simulation model conducted in a hypothetical 
cohort of 10,000 individuals with primary genital herpes in the United States with 
direct medical cost as the principal outcome. Cost estimations are based on literature 
review and national health care databases. A sensitivity analysis through a Monte 
Carlo simulation will assess the validity of the cost estimates. RESULTS: The transition 
of valacyclovir to OTC status will amount to an average annual savings of $707 
($544–$868) per newly infected individual in the form of direct medical expenditures. 
The annual average cost for the OTC transition is $108 per newly infected, compared
to the annual average cost of the prescription based requirement of $815 per newly
infected. Aggregate annual savings to the United States from newly infected individuals 
is $282 million per year. CONCLUSIONS: Transitioning valacyclovir to OTC status 
is a cost saving measure for society, largely due to the decrease in physician ofﬁ ce visits 
for valacyclovir prescriptions. Further studies will need to address speciﬁ c population 
needs in regards to herpes education, feasibility of self-diagnosis, viral resistance and
indirect cost.
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OBJECTIVES: Studies in Mexico have shown that the health expenditure attributed
to antirretroviral treatments for naïve and experimented patients is high. This has an 
impact on the national budget of the public health institutions, especially for units
from the Ministry of Health which deal with the largest number of HIV/AIDS cases
in the country. The objective of this analysis was to estimate the ﬁ nancial impact of 
increasing the availability of atazanavir for the treatment of patients with HIV/AIDS 
in the MoH institutions. METHODS: A budgetary impact model based on epidemio-
logical data, treatment costs and market uptake for four proteasa inhibitors (PI) in a 
time horizon of ﬁ ve years was developed. A baseline scenario, where the current 
PIs market distribution remains the same, was compared with a scenario where 
atazanavir availability is increased. RESULTS: The estimated numbers of infected
HIV/AIDS subjects will grow around 53.48% in the next ﬁ ve years. As a result,
more resources will be needed to face the increasing burden of the disease. The com-
parisons between the two scenarios show that the estimated budget impact related to 
the acquisition of PI is cost-saving. The estimated savings in 2009 are of US$1.168 
million increasing 3.4 times during the ﬁ ve years period. Savings from the treatment 
of main side effects such as, diarrhea and cholesterol lowering intervention are also
observed (US$ 12,777 and US$17,861 in 2009 respectively). CONCLUSIONS: An 
increase in the utilization of atazanavir represents a good clinical and economic option
for the Mexican MoH in the short and long run. The highest impact in the budget
is produced mainly by the pharmacological costs. However, budget savings are also 
derived from the reduction of treatment costs side effects such as diarrhea and
hypercholesterolemia.
PIN10
BUDGET IMPACT OF ANTIMALARIA DRUG FORMULARY DECISIONS: 
A RETROSPECTIVE ANALYSIS FROM A NIGERIAN TEACHING HOSPITAL
Udezi WA1, Usifoh CO1, Omotayo OA2
1University of Benin, Benin, Edo, Nigeria, 2Faculty of Pharmacy, University of Benin, Benin, Edo, 
Nigeria
OBJECTIVES: To quantify the Budget Impact of antimalaria drug formulary decisions
in a Nigerian Teaching Hospital. METHODS: A retrospective random sample of 
17,000 prescriptions (2001–2008) with the wholesale prices of each prescribed drug 
was collected from pharmacy records. The total number of prescriptions per day, the
date and the therapeutic class of the prescribed drugs were also noted. From this data,
estimates of the proportion of patients that received a particular antimalaria medicine 
and the year of introduction or deletion of the drug from the drug formulary were
made. The costs of a complete dose required for the treatment of a patient suffering
from malaria when prescribed a given antimalaria drug were calculated from the 
extracted wholesale prices. These variables served as input in a stochastic Monte Carlo
model which was built to simulate the Budget Impact of each identiﬁ ed formulary 
decision by subtracting the total cost of drugs in the Old Drug Scenario from that of 
the New Drug Scenario. Negative values represent cost savings. A sensitivity analysis 
was conducted by varying the input parameters by o 50%. RESULTS: Halofantrine 
was introduced into the hospital formulary in 2002 with a resultant signiﬁ cant (p 
0.0001) savings of NGN1.02million with a mean of NGN0.16million. The introduc-
tion of arthemisinin combination therapies (ACTs) in 2005 with the addition of IM 
arthemether in 2007 led to an increase expenditure of NGN3.02million (p  0.0001) 
and NGN0.07million (p  0.171) respectively. In 2008, the number of patients that 
were prescribed ACTs decreased from 80.9% in 2007 to 67.9%. This strategy pro-
duced a cost saving of NGN6.27million which was signiﬁ cant (p  0.0001). Sensitivity 
analysis conﬁ rmed the robustness of the model. CONCLUSIONS: Introduction of 
ACTs into the hospital drug formulary signiﬁ cantly increased drug expenditure. We 
therefore suggest that a CEA of available antimalarials may prove to be a valuable 
tool to this budget holder.
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OBJECTIVES: Previous economic analyses of MRSA-conﬁ rmed cSSTI have not 
included costs related to outpatient parenteral antibiotic therapy (OPAT). The objec-
tive of this analysis was to develop an economic model to estimate medical and 
drug costs within both inpatient and outpatient components of care for treating
MRSA cSSTI. METHODS: A 4-week decision model was developed to estimate the 
direct total, inpatient, and outpatient costs of treating MRSA cSSTI from a U.S. payer 
perspective taking into account successes, failures, and adverse events (AEs). Com-
parators included vancomycin, linezolid, daptomycin, and tigecycline. Published 
literature and database analyses, with validation by experts, provided clinical inputs
and resource use data including MRSA efﬁ cacy, length of stay (LOS), consequences 
of AEs and cSSTI failure, OPAT services, among others. Cost data was derived
from literature and standard CPT coding reimbursements. The base case analysis 
assumed equal efﬁ cacy and equal LOS of 4 days among comparators. Univariate and 
probabilistic sensitivity analyses tested efﬁ cacy, complication rates, LOS, and other
resource use parameters. Costs were reported in 2008US$. RESULTS: Total drug 
acquisition costs were 4–6 times lower for vancomycin compared to tigecycline, 
linezolid, and daptomycin. However, the total 4-week cost of treatment including 
drugs, clinical failures, complications, and OPAT were lowest for linezolid ($8,149), 
followed by vancomycin ($8,974), tigecycline ($10,333), and daptomycin ($11,362). 
Oral linezolid reduced the outpatient medical costs by 10-fold versus IV comparators.
The most sensitive model variables for total cost were the MRSA efﬁ cacy, hospital
LOS, OPAT days, and line placement/complication costs. CONCLUSIONS: Although 
total drug acquisition costs were lower for vancomycin vs. comparators, the model
suggests linezolid provides total cost savings in cSSTI versus IV therapies, particularly
in the outpatient arena. The budget impact of antimicrobials for cSSTI should consider
total medical cost offsets from both inpatient and outpatient perspectives.
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OBJECTIVES: To evaluate the cost-effectiveness of daptomycin versus vancomycin in
complicated skin and soft structure infections (cSSSI). METHODS: A decision analytic 
(DA) model was developed to evaluate the cost-effectiveness of daptomycin versus
vancomycin in cSSSI. The payer perspective was adopted and total direct costs related
to cSSSI were measured. Efﬁ cacy (cure) was deﬁ ned as a patient who was treated
empirically with the study drug, had a positive culture of Methicillin-resistant Staphy-
lococcus aureus did not relapse at the test of cure. Previous literature was used to 
determine the parameters of the model. Costs were determined from 2008 Drug Red 
Book and Decision Support System database. Primary outcome was the incremental
cost-effectiveness ratio (ICER) of daptomycin over vancomycin. One-way sensitivity
analyses was performed for all parameters and presented in a tornado diagram. 
Probabilistic sensitivity analysis was performed on all parameters using 10,000 trial
simulations. RESULTS: In the base-case analysis, daptomycin and vancomycin arms 
had total direct costs of $11,162.88 and $16,307.74, respectively. Cure probabilities
for patients in the daptomycin and vancomycin arms were 51.6% and 40.2%, respec-
tively. Cost-effectiveness ratio for daptomycin and vancomycin were $21,619.78/cure 
